Semax is an ACTH(4–7)-related heptapeptide whose laboratory literature spans metal coordination, cell viability, and molecular-response profiling.
Semax contains an ACTH(4–7) sequence joined to the Pro-Gly-Pro tripeptide. This construction makes sequence identity important: results reported for ACTH fragments, Pro-Gly-Pro, or Semax should not be treated as interchangeable without confirming the exact material used.
In vitro research has characterized Semax binding to copper(II) through spectroscopy and electrochemical methods, while cell-culture assays have examined how that coordination changes measured cellular responses under metal-stress conditions. Separate molecular studies have used gene-expression and transcriptomic tools to identify pathways that may respond to the peptide under defined experimental conditions.
The literature is mechanistic but still heterogeneous. Differences in model, concentration, exposure time, and analytical endpoint limit broad comparisons. These studies support careful sequence-specific assay design; they do not establish safety, efficacy, dosing, administration, or an expected outcome in humans or animals.
Peer-reviewed sources for the research summarised above. VIVO summarises published, third-party science and does not conduct or sponsor this research.